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Is There a Potential of Misuse for
Venlafaxine and Bupropion?
Fabrizio Schifano and Stefania Chiappini*
Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical
Sciences, University of Hertfordshire, Hatfield, United Kingdom
Objective: Traditionally, studies on the non-medical use of pharmaceutical products
have focused on controlled substances; e.g., opiates/opioids; and benzodiazepines.
Although both bupropion and venlafaxine have been reported as being misused,
only anecdotal reports have been made available so far. Hence, the European
Monitoring Agency (EMA) Adverse Drug Reactions (ADRs), misuse/abuse/dependence
and withdrawal, venlafaxine- and bupropion-related, database was here analyzed.
Methods: All EMA spontaneous reports relating to venlafaxine (2005–2016) and
bupropion (2003–2016) notifications were here analyzed, to provide a descriptive analysis
by source, gender, age, and type of report. The UK-based, 2000–2016, Yellow Card
Scheme pharmacovigilance database, bupropion and venlafaxine withdrawal reports
were compared as well with those pertaining to fluoxetine and paroxetine.
Results: Out of 20,720 (bupropion) and 47,516 (venlafaxine) total number of
ADRs, some 2,232 (10.8%), and 4,071 (8.5%) misuse/abuse/dependence ADRs
were respectively associated with bupropion and venlafaxine. Conversely, bupropion
withdrawal-related ADRs were here reported in 299/20,720 (1.44%) cases and in
914/47,516 (1.92%) cases for venlafaxine. Overall, all bupropion and venlafaxine
misuse-/abuse-/dependence- and withdrawal-ADRs were related to a respective
number of 264 and 447 patients. According to the Proportional Reporting Ratio (PRR)
computation, in comparison with venlafaxine bupropion resulted to be more frequently
misused/abused (PRR: 1.50), but less frequently associated with both dependence
(PRR: 0.92) and withdrawal (PRR: 0.77) issues. Yellow Card Scheme data suggested
that paroxetine and venlafaxine, in comparison with fluoxetine and bupropion, were
associated with higher number of withdrawal-related reports.
Conclusions: The dopaminergic, stimulant-like, bupropion activities may be associated
with its possible recreational value. Present data may confirm that the occurrence of a
withdrawal syndrome may be a significant issue for venlafaxine-treated patients.
Keywords: antidepressant misuse, bupropion abuse, venlafaxine dependence, venlafaxine withdrawal, EMA,
Yellow Card Scheme, paroxetine, fluoxetine
Schifano and Chiappini Analysis of the EMA Database
INTRODUCTION
The misuse or abuse of prescription drugs is a recently
emerging issue, becoming a reason of public concern (Schifano
et al., 2015). Intentional misuse of prescribing medications
involves gabapentinoids (Chiappini and Schifano, 2016);
anticholinergics (Schifano and di Costanzo, 1991); a range of
stimulants (Schifano et al., 2015); performance- and image-
enhancing drugs (Schifano et al., 2015); and a few antipsychotics
(Chiappini and Schifano, 2018). Although a worldwide rise
of antidepressant (ADs) consumption (Kantor et al., 2015;
OECD Indicators, 2015) has been described, there are only a few
studies relating to the AD potential of misuse and withdrawal.
The selective serotonin reuptake inhibitors/SSRIs have already
been reported to be associated with a risk of both dependence
and an early and late onset (Fava et al., 2015) occurrence
of withdrawal syndrome (Chouinard and Chouinard, 2015;
Cosci et al., 2015). However, according to an updated (July
2017) PubMed/Medline/Embase literature review here carried
out, a few further ADs, e.g., bupropion and venlafaxine, have
emerged as increasingly being misused (Evans and Sullivan,
2014; Schifano et al., 2015; Anderson et al., 2017); the following
represents an overview of most significant related findings.
Bupropion and Venlafaxine; Overview of
Clinical Pharmacological and Misusing
Issues
Bupropion is a second-generation AD that acts as a selective
inhibitor of catecholamines’ (noradrenaline and dopamine)
reuptake, devoid of any serotonergic; antihistamine; or
anticholinergic properties (Stahl et al., 2004). Furthermore,
bupropion is a non-competitive antagonist of nicotinic
acetylcholine receptors (Guzman, 2018), hence being prescribed
for both major depressive episodes and as an aid in smoking
cessation (EMA, 2003). Bupropion is also used ‘off label’ in a
range of conditions, including: attention deficit/hyperactivity
disorder, chronic fatigue, sexual dysfunction, and obesity.
Bupropion adverse events typically include dry mouth, nausea,
and insomnia.
Known as “welbys,” “wellies,” “dubs,” or “barnies,” its
recreational use by oral or nasal routes was first described
some 15 years ago (McCormick, 2002; Welsh and Doyon, 2002;
GSK, 2016). More recently, reports of high-dose bupropion
injecting have appeared as well (Baribeau and Araki, 2013), with
people misusing the drug to get a “high” similar to the one
obtained through other stimulants, such as cocaine. Adverse
effects range from nasal pain to irritability, agitation, cardiac
toxicity, hallucinations and seizures (Rettew and Hudziak, 2006;
Stall et al., 2014). Schifano et al. (2015) analyzing specialized
web fora posts related to the potential misuse/non-medical
use of bupropion compared with amitriptyline and venlafaxine,
identified a total of 7,756 references to at least one of them,
and 668 (8.61%) of them referencing misuse or non-medical
use of one of the three ADs, with bupropion accounting for
438 (65.6%). The most commonly reported desired effects
were similar to stimulants with bupropion; sedative with
amitriptyline; and dissociative with venlafaxine. The nasal route
of administration was most frequently reported for bupropion,
whereas the oral route was most frequently reported for
amitriptyline and venlafaxine. Stassinos et al. (Stassinos and
Klein-Schwartz, 2016) carried out a 14-year retrospective review
on bupropion cases of intentional abuse reported to the US
National Poison Data System, and identified 975 cases, with a
prevalence increasing by 75%, from 2000 to 2012. Most cases
were 13 to 29 years old (67.4%), with typical clinical effects
being tachycardia (57.0%), seizures (33.5%), agitation/irritability
(20.2%), hallucinations/delusions (14.0%), and tremor (13.1%).
Most exposures were ingestions (745) followed by insuﬄation
(166). Final management sites were predominantly emergency
department (36.9%) and admission to critical care unit (27.3%)
according to Toxnet (Toxnet, Toxicology Data Network, 2015).
In line with this, a 2004–2011 search on the US Drug Abuse
Warning Network (DAWN) system identified 210 cases of
possible bupropion misuse and abuse, and in a minority of
cases the molecule resulted to be snorted or injected (GSK,
2016).
Bupropion is a cathinone derivative (Lewin et al., 2014);
similar to remaining molecules of this class, one could argue
that its diversion potential and reinforcement of misuse may
be related to its dopaminergic and noradrenergic effects (Vento
et al., 2013). Most bupropion abusers present with a history of
drug addiction (Khurshid and Decker, 2004; Hill et al., 2007;
Langguth et al., 2009; Kim and Steinhart, 2010; Reeves and
Ladner, 2013; Yoon and Westermeyer, 2013); higher prevalence
levels have been identified in inmates, and this has brought to
bupropion removal of from some US prison formularies (Laird
and Narayan, 2009; Phillips, 2012; Hilliard et al., 2013).
Venlafaxine is indicated (HSCIC, 2016) for the treatment
of major depressive episodes, generalized anxiety disorder and
social phobia, with off-label uses including obsessive-compulsive
disorder, and chronic pain syndromes (EMA, 2007). It is available
both as an immediate and extended-release (XR) formulation;
XR pills contain spherules in coated or encapsulated form which,
when broken, release the medication rapidly (Muth et al., 1986).
Venlafaxine is a phenylethylamine derivative inhibiting the
reuptake of serotonin/5-HT; norepinephrine/NE; and to a lesser
extent dopamine/DA (Bolden-Watson and Richelson, 1993;
Redrobe et al., 1998). The reuptake effects of venlafaxine are
dose-dependent, with action on 5-HT transmission at low doses
(<150 mg/day); on both 5-HT and NE systems at moderate
doses (>150 mg/day); and on DA at high doses (>300 mg/day)
(Harvey et al., 2000; Stahl, 2013). In the prefrontal cortex
nerve terminals there are only few DA, but plenty of both NE
and 5-HT, transporters (Weikop et al., 2004). Hence, if DA
is released, it is free to circulate from the synapses, with huge
prefrontal cortex levels of DA increase being recorded (Shang
et al., 2007). Venlafaxine main active metabolite, desvenlafaxine,
presents with large levels of NE transporter inhibitory activities,
further increasing levels of DA turnover in the prefrontal cortex
(Shang et al., 2007). Both venlafaxine and its metabolite do not
possess any monoamine oxidase inhibitory activity, which is
responsible for the degradation of DA (Maj and Rogóz, 1999;
Shang et al., 2007). Preclinical studies showed that venlafaxine
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presents with a high affinity for D2 receptors (Bolden-Watson
and Richelson, 1993; Shang et al., 2007), whilst its chronic
administration is associated as well with D3 receptors’ adaptive
changes. Finally, venlafaxine desensitizes both 5-HT1A and beta
adrenergic receptors (Maj and Rogóz, 1999), but virtually no
affinity has been demonstrated for opiate; benzodiazepine;
phencyclidine; N-methyl-D-aspartate; muscarinic; α1-
adrenergic; or histaminergic receptors. Venlafaxine abrupt
discontinuation may be associated with a withdrawal syndrome
(Rudolph and Derivan, 1996; Augustin et al., 1997; Parker and
Blennerhassett, 1998; Campagne, 2005; Taylor et al., 2005; Sabljic´
et al., 2011; Carvalho et al., 2016), characterized by nausea,
depression, suicidal thoughts, disorientation, stomach cramps,
panic attacks, sexual dysfunction, headache, and occasional
psychotic symptoms (Koga et al., 2008); in some cases, the
clinical picture may resemble a stroke (Campagne, 2005).
Although how the withdrawal syndrome develops is unknown,
it may well be associated with electrophysiological changes in
5-HT receptors. This is similar to what can be observed with
the SSRIs, although the severity of withdrawal may be higher
with venlafaxine (Fava et al., 1997). SSRIs and SNRIs have
replaced the habit-forming benzodiazepines for the treatment of
anxiety (Cosci et al., 2015), however dependence and withdrawal
symptoms associated with newer ADs have been described
(Sir et al., 2005; Stahl et al., 2005; Llorca and Fernandez,
2007; Kotzalidis et al., 2008; Fava et al., 2015). Consistent with
this, Kelly et al. (Kelly et al., 2014) observed that cannabis-
dependent participants with depressive disorder are less likely
to achieve abstinence when exposed to venlafaxine treatment,
suggesting that withdrawal-like symptoms led to continued
marijuana smoking in this group. Finally, since venlafaxine and
its metabolites cross the placenta, even the newborn can be
exposed to the risk of a discontinuation syndrome, which is at
times associated with encephalopathy or paroxysmal episodes
(Holland and Brown, 2017). Although venlafaxine withdrawal
can successfully be managed with a short course of duloxetine
(Cutler, 2017), in order to taper down gradually its dosage
the use of tapering strips, containing a slightly lower dose of
medication on each consecutive day, has been suggested (Groot,
2013). Apart from the occurrence of withdrawal, the intake of
large venlafaxine (“baby ecstasy”) dosages has been reported
(Francesconi et al., 2015). Related effects have anecdotally been
described as amphetamine/ecstasy-like, with the mechanism
behind its putative abuse liability arguably being related to
venlafaxine increased dopaminergic turnover at high dosages
(Shang et al., 2007). In line with this, using wastewater analysis,
Baker et al. (Baker et al., 2014) presented community-wide
estimation of drug and pharmaceuticals’ consumption in
England. Target compounds were compared to NHS prescription
statistics; discrepancies were observed for a range of molecules,
including venlafaxine, suggesting sales of non-prescribed
venlafaxine. Furthermore, Fountain and Slaughter (Fountain
and Slaughter, 2016) carried out a retrospective review of records
of New Zealand National Poisons Centre records referring to the
period 2003–2012; high or rapidly increasing levels of enquiries
were identified for a range of prescribing medicines, including
venlafaxine.
To better define the context for change in ADRs over time,
it may be important to consider bupropion and venlafaxine
prescription rates’ historical information. Although, for a range
of reasons, the worldwide prescription figures for thesemolecules
are not available (Chiappini and Schifano, 2018), England-based
data from the Prescription Cost Analysis (Data.gov.uk, 2016)
were here taken into account as a reference, hence serving as a
general indication of prescription trends. When considering the
available January 2009-December 2016 time-frame, the number
of venlafaxine prescription items dispended increased over time,
from 2.51 (2009) to 3.9million (2016). Conversely, the bupropion
prescribing rates showed here an opposite trend, decreasing from
0.51 to 0.22million, possibly because bupropion is licensed, in the
UK, only as an adjunct in nicotine cessation programmes, and not
as an antidepressant. Over the last few years, a few more nicotine
dependence pharmacotherapies have been made available,
with possible decreasing levels of interest toward bupropion
prescribing.
To assess both venlafaxine and bupropion
misuse/abuse/dependence and withdrawal-related issues,
we aimed here at analyzing the European Medicines Agency
(EMA) EudraVigilance (EV) database (Schifano and di Costanzo,
1991), which collects electronic reports of suspected adverse
drug reactions (ADRs) for all medicinal products authorized in
the European Economic Area/EEA.
METHODS
After a formal request to EMA, we were allowed to access and
analyze the EV ADRs database, relating to all venlafaxine- and
bupropion-related case reports submitted spontaneously up to
mid-July 2016; for a thorough description of the EV database
refer to Chiappini and Schifano (2016, 2018). In order to focus
on misuse; abuse; dependence; and withdrawal issues, in the
two datasets we selected and identified the following ADRs:
“dependence,” “drug abuse,” “drug abuse(r),” “drug dependence,”
“drug diversion,” “drug withdrawal headache,” “drug withdrawal
syndrome,” “intentional product misuse,” “intentional product
use issue,” “substance abuse,” “substance dependence,” and
“withdrawal syndrome.” Specifically, “misuse” was here meant
to be the “intentional and inappropriate use of a product other
than as prescribed or not in accordance with the authorized
product information.” Conversely, “abuse” was here defined
as the “intentional non-therapeutic use of a product for a
perceived reward or desired non-therapeutic effect including,
but not limited to, getting high/euphoria” (MedDRA, 2012).
The term “addiction,” typically replaced by “dependence,” is
the “overwhelming desire to take a drug for non-therapeutic
purposes together with the inability to control or stop its
use despite harmful consequences” (MedDRA, 2012). Finally,
“withdrawal” was here defined as: “a substance-specific syndrome
which follows cessation or reduction in the intake of a
psychoactive substance previously regularly used” (WHO Expert
Committee on Addiction-Producing Drugs, 2016). Withdrawal
is at times considered as an additional indication of misuse,
together with abuse; and dependence-related terms. However,
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although withdrawal symptoms may be indicative of physical
dependence to a range of abusing drugs, there may also be
withdrawal symptoms that are not necessarily related to the
addictive and abuse properties of drugs; this is the case,
for example, of beta blockers (Hopper et al., 2014) and
corticosteroids (Shenouda et al., 2018). Hence, data relating to
withdrawal were presented separately from those pertaining to
misuse; abuse and dependence. To better assess the venlafaxine
and bupropion associated withdrawal issues, we carried out a
further comparison with paroxetine and fluoxetine, two SSRIs
being characterized by different levels of withdrawal presentation
during tapering down regime (Wilson and Lader, 2015). In
doing so, we took into account the January 2000-December
2016 Drug Analysis Profiles pharmacovigilance data (MHRA,
2018) available from the Yellow Card Scheme (Yellow Card,
2018) of the UK-Medicines and Healthcare products Regulatory
Agency (MHRA). MHRA collect reports of ADRs reported from
within the UK, and these reports are then consistently forwarded
to EMA (EMA, 2013), hence formally contributing to the EV
database implementation.
ADRs’ numbers differed from those referring to case reports,
since different reporters/senders could have independently
flagged the same ADR to EMA. We included here those ADRs
which were listed as the “suspect drug,” meaning that the reporter
suspected this drug, and not the concomitant medicine(s), to
have caused the index ADR (Chiappini and Schifano, 2018). To
more properly assess current data, the proportional reporting
ratio (PRR) approach was considered, here defined as: “the ratio
between the frequency with which a specific adverse event is
reported for the drug of interest (relative to all adverse events
reported for the drug) and the frequency with which the same
adverse event is reported for the drug(s) in the comparison group
(relative to all adverse events for drugs in the comparison group;
EMA, 2008). Being a measure of disproportionality, a PRR > 1
suggests that the adverse event is more commonly reported for
individuals taking the drug of interest relative to the comparison
drug(s). The PRR is computed with the help of the following
formula:
W/W+ X
Y/Y+ Z
(where: W = number of bupropion cases relating to the chosen
adverse event(s); X = number of bupropion cases involving any
other adverse events; Y= number of venlafaxine cases relating to
the chosen adverse event(s); and Z= number of venlafaxine cases
involving any other adverse events).
Ethics’ Issues
Because of EMA protection of privacy and integrity of
individuals, certain data elements (e.g., names/identifiers of
individuals involved; country specific information, nationally
authorized products etc.) were here not disclosed. As a
consequence of the database analyzed containing only de-
identified data, and consistent with previous reports (Chiappini
and Schifano, 2016), no specific ethical issues were here
identified.
RESULTS
Out of 20,720 for bupropion, and 47,516 for venlafaxine,
total number of ADRs, some 2,232 (10.8%), and 4,071 (8.5%)
misuse/abuse/dependence ADRs were respectively associated
with bupropion and venlafaxine. Conversely, bupropion
withdrawal ADRs were here reported in 299/20,720 (1.44%)
cases and in 914/47,516 (1.92%) cases for venlafaxine (see
Tables 1, 2).
The total number of ADRs corresponded to 264 and 447
patients respectively prescribed with bupropion (Jan 2005-May
2016) and venlafaxine (June 2003-July 2016).
Over time, both bupropion and venlafaxine reports were
on the increase (Figure 1); bupropion-related ADRs increased
from a number of 48 in 2010 to 553 in 2015. Venlafaxine-
related ADRs had increased since 2003 (110 ADRs), with peaks
in both 2010 (470 ADRs) and 2014 (752 ADRs). In both
bupropion and venlafaxine datasets, most ADRs were submitted
by European Economic Area (EEA)-based pharmaceutical
companies, respectively in 2,393/2,531 (94.5%) and 4,156/4,985
(83.3%) instances, with residual cases having been submitted
by relevant international regulatory authorities. The bupropion
drug role was judged by the reporter as “suspect” in 1,826
reports out of 2,531 (72.1%), whilst for venlafaxine the same
occurred in 3,260/4,985 (65.4%) cases. For bupropion, subjects
typically involved were adult males; conversely, adult females
were mostly represented in venlafaxine cases. Concomitant
drugs reported in bupropion cases mostly included: prescribing
opiates/opioids (n = 123/264 cases; 46.5%); and antidepressants
(n = 116/264; 43.9% of cases), with SSRIs and SNRIs
being respectively reported in 90 and 10 cases. Concomitant
drugs reported in venlafaxine cases included: prescribing
opiates/opioids (n = 150/447 cases, 33.55%); benzodiazepines
(n = 138/447; 30.8%); and antidepressants (n = 114/447; 25.5%)
with SSRIs and SNRIs having been respectively reported in
70 and 18 cases. From the available data, it appeared that
bupropion was administered above the therapeutic range (>300
mg/day) in seven cases, with a maximum recorded dosage of
3,000mg. Conversely, the venlafaxine dosage was higher than
the maximum typically recommended (e.g., 375mg) in 13 cases,
with the highest dosage recorded being 6,300mg. Venlafaxine
extended-release formulation was reported in 128/447 (28.6%)
cases. Bupropion injecting and snorting intake practices were
respectively reported in 13 and 21 cases, typically in combination
with recreational drugs and/or prescribing opiates/opioids.
Conversely, venlafaxine injecting and snorting intake practices
were respectively reported in five and four cases, with this intake
having been associated with cannabis; opiates/opioids; cocaine;
and midazolam.
To better compare bupropion and venlafaxine addictive
liability levels, the PRR values were computed for each ADR
class (e.g., drug misuse/abuse; dependence; and withdrawal). As
it appears from the following calculation, misuse/abuse ADRs
appeared to be more frequently reported for bupropion than
venlafaxine:
W/W+ X
Y/Y+ Z
=
1, 558/1, 558+ 18, 189
2, 361/2, 361+ 42, 531
=
0.07889
0.05259
= 1.50
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TABLE 1 | Overview of data relating to bupropion and venlafaxine ADRs as reported to the EV database.
Bupropion ADRs Venlafaxine ADRs
Time-frame considered 01/2005–05/2016 06/2003–07/2016
Total number of ADRs 20,720 47,516
Misuse-/abuse-/dependence- and withdrawal- related
ADRs
2,531
(including misuse-/abuse-/dependence-related ADRs
2,232 and withdrawal-related ADRs 299)
4,985
(including misuse-/abuse-/dependence-related ADRs
4,071 and withdrawal-related ADRs 914)
Number of unique patients being reported to the
database
264 447
Age range most typically represented 18–64 yy (64.5%) 18–64 yy (61.48%)
ADRs most typically represented within the
misuse-/abuse-/dependence- and withdrawal- related
ADRs’ group
Drug abuse (61.6%), drug dependence (26.6.0%),
drug withdrawal syndrome (11.8%)
Drug abuse (47.4%), drug dependence (34.3%), drug
withdrawal syndrome 18.3(%)
Gender most typically represented Male (F/M ratio: 1,155/1,257 = 0.91) Female (F/M ratio: 2,483/2,406 = 1.03)
Concomitant drugs most typically represented Opiates/opioids (in n = 123/264; 46.5 %); other
antidepressants (in n = 116/264; 43.9% of cases,
with SSRIs-citalopram, escitalopram, fluoxetine,
paroxetine and sertraline being those most typically
reported); other psychotropic substances, such as
amphetamine, caffeine, cannabis, cocaine, ethanol,
nicotine (in n = 68/264; 25.7%)
Opiates/opioids (in n = 150/447,33.55% of cases);
benzodiazepines (in n = 138/447; 30.8%); and other
antidepressants (in n = 114/447; 25.5% with SSRIs
being those most typically reported)
TABLE 2 | Bupropion and venlafaxine misuse/abuse-; dependence-; withdrawal and remaining-related ADRs’: occurrence and proportional reporting ratio (PRR).
Bupropion ADRs No. of reactions ADRs Proportion of bupropion ADRs Bupropion vs. venlafaxine PRR
Misuse/abuse-related ADRs (A1) 1,558 0.075 1.50
Dependence–related ADRs (A2) 674 0.032 0.92 (reverse: 1.09)
Withdrawal-related ADRs (A3) 299 0.014 0.77 (reverse: 1.30)
Other Adverse Events (B) 18,189 0.878
Total (A1+A2+A3 +B) 20,720 1
Venlafaxine ADRs No. of reactions ADRs Proportion of venlafaxine ADRs
Misuse/abuse-related ADRs (C1) 2,361 0.05
Dependence–related ADRs (C2) 1,710 0.036
Withdrawal syndrome-related ADRs (C3) 914 0.019
Other adverse events (D) 42,531 0.895
Total (C1+C2+C3+D) 47,516 1
Conversely, PRR values for dependence and withdrawal resulted
to be respectively 0.92 and 0.77, meaning that these ADRs
were more frequently represented in venlafaxine-, as opposed to
bupropion-, related reports (for all computations, see Table 2).
According to the MHRA Yellow card Scheme, the number of
paroxetine, venlafaxine, fluoxetine and bupropion withdrawal-
related ADRs resulted to be as follows: paroxetine: 1,358
reports out of a total number of 18,988 (7.1%); venlafaxine:
471/11,350 (4.2%); fluoxetine: 74/7,905 (0.93%); bupropion:
30/20,585 (0.14%; Table 3). In comparison with the remaining
3 ADs, bupropion was associated with the lowest values of
PRR (venlafaxine vs. bupropion PRR = 29.64; paroxetine
vs. bupropion PRR = 51.07), whilst venlafaxine presented
with withdrawal PPR values second only to those relating
to paroxetine (paroxetine vs. venlafaxine PRR: 1.72).
Finally, within the SSRI group paroxetine vs. fluoxetine
PRR values resulted to be of 7.61, suggesting a higher
risk of withdrawal in those prescribed with paroxetine (see
Table 3).
DISCUSSION
This study aimed at systematically identifying and
analyzing venlafaxine-, as opposed to bupropion-,
misuse/abuse/dependence and withdrawal issues. Present
data have been extracted from a high-quality and large scale
pharmacovigilance database, such as the EMA’s EV that, together
with theWorld Health Organization’s DrugMonitoring Program
(WHO’s Drug Monitoring Programme, 2016), is considered a
worldwide reference standard. Most related literature papers,
so far, were based on small case series/single case studies
(Quaglio et al., 2008; Vento et al., 2013). Conversely, current
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FIGURE 1 | Data related to ADRs rates by year.
TABLE 3 | Reported withdrawal adverse drug reactions for bupropion; fluoxetine;
paroxetine; and venlafaxine (source: UK-based Yellow Card scheme; 2000–2016)
and related PRR computations.
No. of reactions Proportion PRR computation
Bupropion 0.0014 Venlafaxine vs.
Bupropion
29.64
Withdrawal
reactions
30 Fluoxetine vs.
Bupropion
6.71
Total reactions 20,585 Paroxetine vs.
Bupropion
51.07
Fluoxetine 0.0094 Venlafaxine vs.
Fluoxetine
4.41
Withdrawal
reactions
74 Paroxetine vs.
Venlafaxine
1.72
Total reactions 7,905 Paroxetine vs.
Fluoxetine
7.61
Paroxetine 0.0715
Withdrawal
reactions
1,358
Total reactions 18,988
Venlafaxine 0.0415
Withdrawal
reactions
471
Total reactions 11,350
findings refer to much larger numbers of patients, respectively
presenting with either bupropion (264 patients) or venlafaxine
(447 patients) misuse/abuse/dependence and withdrawal issues.
Current data and PRR values may tentatively suggest that the
misuse/abuse-ADRs were more represented in bupropion cases,
whilst both dependence- and withdrawal-related cases were
more frequently reported for venlafaxine. Yellow Card Scheme
data seemed to confirm that venlafaxine presented indeed with
a higher risk of withdrawal in comparison with bupropion.
Furthermore, venlafaxine withdrawal occurrence risk may be
smaller, but somehow comparable, to that of paroxetine. Indeed,
several papers have identified the occurrence of withdrawal
signs/symptoms relating to a range of ADs, and especially SSRIs
(Addictionblog.org, 2012; Harvey and Slabbert, 2014; Fava et al.,
2015). The characteristics of the discontinuation syndrome have
been linked to the half-life of a given SSRI, which can explain
the low levels of fluoxetine discontinuation syndrome here
identified (Wilson and Lader, 2015) The range of idiosyncratic
(e.g., insuﬄation; parenteral/intravenous) intake modalities were
here more frequently identified in bupropion, as opposed to
venlafaxine cases. Overall, the misuse/abuse/dependence and
withdrawal ADRs were here associated, for both molecules and
albeit of a small proportion of cases, with supra-therapeutic, or
even extraordinarily high dosages.
Although there may be no straightforward explanations
for these results, the dopaminergic, stimulant-like, bupropion
activities (Vento et al., 2013) may be associated with its possible
recreational value. Indeed, when bupropion tablets are crushed
and snorted, a high dose of the molecule is being delivered
directly into the bloodstream, hence overcoming the slow-
release mechanism which is typical of bupropion tablets (Renoir,
2013). Conversely, the occurrence of withdrawal phenomena
after the abrupt discontinuation of venlafaxine has already been
extensively described, being a real risk for each venlafaxine-
treated patient (Sabljic´ et al., 2011). Present data focus on misuse;
abuse; dependence; and withdrawal, but these are not the same
issues. Although, similar to what described with the SSRIs, the
occurrence of a withdrawal syndrome may be interpreted as
being associated with a “dependence” condition (Fava et al.,
2015), this may not necessarily be an indication, per se, of an
index drug possessing a misuse/recreational value (Shang et al.,
2007).
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Apart from benzodiazepines and opiates/opioids, other ADs
(mostly SSRIs) were those drugs most frequently identified in
combination with both bupropion and venlafaxine. Indeed, this
may suggest the comorbid presence of depression with substance
misuse conditions. Unfortunately, however, the EV database did
not provide here further details of clinical interest, including:
possible concurrence of psychopathological conditions;
medication dosage prescribed prior to discontinuation;
range/intensity of withdrawal symptoms; and time-frame
of the clinical presentation of withdrawal. Both bupropion and
venlafaxine ADRs seemed to have increased over time. It is
unclear if these trends had just mirrored the increasing rates
of worldwide prescribing of these molecules. In fact, whilst
English PCA data confirmed venlafaxine increase in prescribing
levels in the 2009–2016 time frame, an opposite trend was
identified for bupropion. Hence, one could hypothesize
that the bupropion misuse increasing rates over time here
identified were somehow facilitated by the progressively
increasing numbers of rogue, non-prescription required,
drug-vending web sites (Deluca et al., 2012; Nelson et al.,
2014).
Limitations
Some considerations are needed with respect to the dataset
analyzed. Firstly, the number of case reports for a particular
medicinal product may depend on its availability on the market
and extent of use, as well as the public awareness of a safety
concern. Moreover, the comparison here considered between
venlafaxine and bupropion may be difficult, since it assumes that
these drugs have similar levels of both worldwide prescription
and adverse effects. Unfortunately, however, global prescribing
figures are not available due to the wide differences in both
availability and collection of prescription data around the
world.
Case reports of suspected ADRs alone are rarely sufficient
to confirm that a certain effect in a patient has been caused by
a specific medicine. The fact that a suspected adverse reaction
has been reported does not necessarily mean that the medicine
has caused the observed effect, as this could have also been
caused by the disease being treated, another illness, or it could
be associated with another medicinal product taken by the
patient at the same time. Also, as reports are spontaneously
submitted, several ADRs relating to the same patient were
here identified. This may have happened because of a range
of different sources reporting the same ADR but also because
a number of different ADRs may have been reported for
the same patient. For this reason, report duplications may
occur indeed, e.g., where a healthcare professional reported the
same suspected ADR to both the national regulator and the
Marketing Authorization Holder, and both eventually reported
the index ADR to the EV. Finally, due to the nature of
spontaneous reports, not all data fields (such as subjects’
possible psychiatric/drug misuse history) were provided for all
reports.
CONCLUSIONS
Despite data collection limitations, and although further studies
are clearly needed, both the literature and current EMA data
may suggest that, in comparing these two molecules, bupropion
appeared to be prone to misuse/abuse (Orsolini et al., 2015;
Stassinos and Klein-Schwartz, 2016), whilst venlafaxine was
more frequently reported as being associated with withdrawal.
Present data may help the clinician in making a more informed
decision about AD prescribing. One could argue, for example,
that bupropion should be prescribed with caution in clients
with a history of substance misuse, whilst venlafaxine and
paroxetine dosage should be tapered down gradually, with
the possibility of switching to fluoxetine prior to withdrawal
(Wilson and Lader, 2015). Whether these abuse and withdrawal
issues occur on a large scale cannot be confirmed from
here but, as the EV reports were submitted spontaneously,
present figures may only underestimate the magnitude of the
problem.
The reasons for non-medical use of prescription drugs are
complex. However, a range of factors may well facilitate this
occurrence, including: perception of prescription drugs’ non-
medical use as being more socially acceptable, less stigmatized,
and safer (Hu et al., 2016) than the intake of scheduled/illicit
substances; and likely lack of detection in standard drug screens.
Healthcare professionals should be vigilant when prescribing
any psychotropics, including ADs (Carvalho et al., 2016),
and particularly so to inmates and/or those with a substance
misuse history. The amount of drug prescribed per individual
prescription should be limited; and, if any related misuse issues
are being identified, physicians should consider medication
tapering (Evans and Sullivan, 2014).
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